Research & Education

ALK IHC Shown to Be Sensitive and Accurate in NSCLC

Findings Support Algorithmic Use of Test in Evaluation of NSCLC

DENVER – A new study shows that immunohistochemical (IHC) analysis is sensitive, specific, and accurate for detecting ALK protein expression based on gene rearrangement in non-small cell lung cancer (NSCLC).

ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy


Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.

ELCC 2014: Late and Chronic Toxicities of New Targeted Therapies


Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.

ELCC 2014: Cabazitaxel Fails to Meet the Primary Endpoint in a Randomised Phase II Study in SCLC Patients

Cabazitaxel failed to meet a primary endpoint of showing superior progression-free survival (PFS) and additionally showed less favourable median overall survival (OS) compared to topotecan in an international, randomised open-label phase II trial performed in patients with small-cell lung cancer (SCLC), who had progressed during or after first-line platinum-based chemotherapy

ELCC 2014: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening

In search of non-invasive biomarkers

A group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial.

ELCC 2014: Phase I Study of CO-1686 in Patients with EGFR Mutated Recurrent, Advanced NSCLC

CO-1686 has demonstrated a good tolerability and promising efficacy against T790M+ epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).